reports
- Nicholas Cortellucci
- CFA
RKV: A Catalyst Heavy Oncology Story
What you need to know: • Rakovina has a portfolio of three DNA Damage Response Inhibitor drug candidates that address specific shortcomings of existing treatments. • Rakovina’s lead kt-3000 program is designed to inhibit both PARP and HDAC enzymes; the candidate is expected to begin human trials in H1/24. • RKV’s management team and partnership with UBC far exceed what we would expect from a
InvestmentPitch Media Video Discusses Rakovina Therapeutics and its Pr...
InvestmentPitch Media Video Discusses Rakovina Therapeutics and its Presentation of Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research Annual General Meeting VANCOUVER, British Columbia, April 14, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, presented at the American Association of Cancer Research Annual Meeting. For more information, please view the I...
Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022
Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022 VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV:RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response (DDR) technologies, is pleased to announce that it is presenting virtually at the Biotech Showcase™ 2022 conference, which is being held virtually January 10-12 and January 17-19, 2022. Registered attendees to Biotech Showcase can access Rakovina Therapeutics’ pre-recorded company presentation prior to th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.